Implantica (IMP) Q2 2024 earnings summary

Executive summary

• Net sales rose 59% year-over-year in Q2 2024 to EUR 554,000, driven by RefluxStop adoption among key European centers and strong clinical and market momentum.

• Operating loss (EBIT) widened to EUR 5.87 million in Q2, mainly due to increased R&D spending for FDA submissions.

• Cash position remains strong at EUR 74 million at quarter-end, with no interest-bearing debt and an equity ratio of 96%.

• RefluxStop continues to gain clinical validation, with multiple independent studies published showing excellent outcomes, especially for difficult-to-treat GERD subgroups.

• Regulatory progress includes completion of FDA PMA Module I review with only minor findings and ongoing NICE IPAC evaluation in the UK.

Financial highlights

• Q2 2024 net sales reached EUR 554,000, up 59% year-over-year, with H1 net sales at EUR 1.15 million, up 75%.

• Adjusted gross margin was 91% in Q2 and H1, down from 94% last year.

• Operating loss (EBIT) was EUR 5.87 million in Q2 and EUR 12.96 million for H1, mainly due to higher R&D costs.

• Net cash outflow from operating activities was EUR 6.3 million in Q2; cash balance at quarter-end was EUR 74 million.

• Basic and diluted loss per Class A share was EUR 0.09 in Q2.

Outlook and guidance

• Near-term focus on FDA approval for RefluxStop, with Module 2 filing imminent and approval expected in 2024 or 2025, pending FDA site visits.

• US market launch targeted at 20-30 leading centers, pending FDA approval; no significant timeline impact expected from current regulatory process.

• Final NICE IPAC decision in the UK expected by H1 2025.

• Anticipates continued investment in clinical trials but plans to offset costs by reducing other outlays.

• Expects to scale commercial operations in the U.S. and Europe, leveraging strong clinical evidence and KOL engagement.